Karyopharm Therapeutics (KPTI) Upgraded at BidaskClub
BidaskClub upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a sell rating to a hold rating in a report published on Monday morning.
A number of other research firms have also weighed in on KPTI. ValuEngine lowered shares of Karyopharm Therapeutics from a strong-buy rating to a buy rating in a research report on Thursday, October 11th. HC Wainwright reissued a buy rating and set a $30.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, November 7th. Wedbush raised shares of Karyopharm Therapeutics from a neutral rating to an outperform rating and set a $19.00 price target on the stock in a research report on Friday, November 9th. B. Riley began coverage on shares of Karyopharm Therapeutics in a research report on Friday, November 30th. They set a buy rating and a $23.00 price target on the stock. Finally, Bank of America raised shares of Karyopharm Therapeutics from an underperform rating to a neutral rating in a research report on Thursday, January 3rd. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $21.90.
KPTI stock traded down $0.21 during midday trading on Monday, hitting $9.96. The company’s stock had a trading volume of 5,338 shares, compared to its average volume of 580,482. The firm has a market capitalization of $621.04 million, a P/E ratio of -3.56 and a beta of 3.36. Karyopharm Therapeutics has a twelve month low of $8.01 and a twelve month high of $21.71.
In related news, insider Sharon Shacham sold 12,500 shares of the firm’s stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $10.23, for a total transaction of $127,875.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael Kauffman sold 9,600 shares of the firm’s stock in a transaction dated Monday, November 26th. The stock was sold at an average price of $11.00, for a total transaction of $105,600.00. Following the sale, the chief executive officer now owns 521,743 shares of the company’s stock, valued at approximately $5,739,173. The disclosure for this sale can be found here. Insiders have sold 57,500 shares of company stock worth $636,231 over the last three months. 13.26% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of KPTI. BlackRock Inc. increased its holdings in Karyopharm Therapeutics by 47.0% during the second quarter. BlackRock Inc. now owns 4,055,634 shares of the company’s stock worth $68,905,000 after buying an additional 1,297,571 shares during the last quarter. Candriam Luxembourg S.C.A. increased its holdings in Karyopharm Therapeutics by 120.6% during the third quarter. Candriam Luxembourg S.C.A. now owns 1,085,500 shares of the company’s stock worth $18,486,000 after buying an additional 593,500 shares during the last quarter. Macquarie Group Ltd. purchased a new stake in Karyopharm Therapeutics during the second quarter worth about $5,787,000. Federated Investors Inc. PA increased its holdings in Karyopharm Therapeutics by 11,995.4% during the third quarter. Federated Investors Inc. PA now owns 295,854 shares of the company’s stock worth $5,038,000 after buying an additional 293,408 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in Karyopharm Therapeutics by 51.5% during the second quarter. Northern Trust Corp now owns 601,974 shares of the company’s stock worth $10,226,000 after buying an additional 204,680 shares during the last quarter. Institutional investors and hedge funds own 71.21% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Read More: Yield Curve
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.